Correa, Denise D.
Kryza-Lacombe, Maria
Baser, Raymond E.
Beal, Kathryn
DeAngelis, Lisa M.
Funding for this research was provided by:
Society of Memorial Sloan Kettering Cancer Center
National Cancer Institute (P30 CA008748 - Core Grant)
Article History
Received: 12 October 2015
Accepted: 26 December 2015
First Online: 6 January 2016
Compliance with ethical standards
:
: Dr. Correa serves on the Editorial Board of <i>Neuro</i>-<i>Oncology Practice</i> and on the Neurotoxicity Advisory Board for Juno Therapeutics. Mr. Baser reports no disclosures, Ms. Kryza-Lacombe reports no disclosures, Dr. Kathryn Beal reports no disclosures,.Dr. DeAngelis serves on the Editorial Board of <i>Neurology, Journal of Neuro</i>-<i>Oncology, Neuro</i>-<i>Oncology, Neuro</i>-<i>Oncology Practice, and The British Medical Journal</i>. She serves on the Neurotoxicity Advisory Board for Juno Therapeutics. She serves as a Mentor for CTSC KL2 Scholar Award, KL2TR000458; A Pilot Trial of Enoxaprin vs. Aspirin in Patient with Cancer and Stroke.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.